# Cyclophosphamide-Induced Hemorrhagic Myocarditis

## TL;DR

A 63-year-old man developed rare cyclophosphamide-induced hemorrhagic myocarditis after a high-dose chemotherapy regimen for myelofibrosis.

## Contribution

This is the first reported case of nonfatal hemorrhagic myocarditis at a cyclophosphamide dose below 100 mg/kg.

## Key findings

- The patient showed elevated cardiac biomarkers and echocardiographic changes consistent with myocarditis.
- Cardiac MRI indicated myocardial edema, inflammation, and intramyocardial hemorrhage.
- Multimodal cardiac imaging was critical for diagnosis and management of the condition.

## Abstract

Cyclophosphamide is a widely used chemotherapeutic agent with a spectrum of toxicities, including a rare drug-related hemorrhagic myocarditis.

A 63 -year-old male with myelofibrosis underwent haploidentical stem cell transplantation with 95 mg/kg cyclophosphamide conditioning. He developed tachycardia, lower-extremity edema, and pulmonary congestion 8 days later. Troponin-T was 512 ng/L, and N-terminal pro-brain natriuretic peptide was 20,142 pg/mL, each previously normal. Electrocardiogram showed low-voltage QRS complexes in limb leads. Echocardiography demonstrated significant left ventricular wall thickening (17 mm), preserved left ventricular ejection fraction (54%), and decreased global longitudinal strain (−9%), all previously normal. Cardiac magnetic resonance imaging suggested myocardial edema and inflammation. Left ventricular T2∗ value near 20 ms suggested intramyocardial hemorrhage. Volume overload and supraventricular arrhythmias were managed conservatively.

To our knowledge, there are no reported cases of nonfatal cyclophosphamide-induced hemorrhagic myocarditis at a dose <100 mg/kg.

An expedited multimodal cardiac imaging approach is warranted when this rare cardiotoxicity is suspected.